Quarterly ResultAug 5, 2026, 07:07 AM
BioCryst Q2 Revenue $218.3M; Raises Full-Year Total Revenue Guidance
AI Summary
BioCryst Pharmaceuticals reported strong second-quarter 2026 financial results, with total net revenue increasing 34% year-over-year to $218.3 million and ORLADEYO net revenue reaching $158.2 million. The company achieved a GAAP operating profit of $98.5 million and a Non-GAAP operating profit of $113.2 million. BioCryst raised its full-year 2026 total revenue guidance to $690 million to $715 million and improved its non-GAAP operating expense outlook. Key corporate developments include the launch of ORLADEYO oral pellets for pediatric patients and the completion of enrollment in the pivotal navenibart study.
Key Highlights
- Total net revenue reached $218.3 million in Q2 2026, a 34% increase year-over-year.
- ORLADEYO net revenue was $158.2 million, up 10% year-over-year on a comparable basis.
- Reported GAAP operating profit of $98.5 million and Non-GAAP operating profit of $113.2 million.
- Increased full-year 2026 total revenue guidance to $690 million to $715 million.
- Maintained full-year 2026 ORLADEYO revenue guidance of $625 million to $645 million.
- Began shipping ORLADEYO oral pellets for pediatric patients on August 3, with 47 prescriptions written year-to-date.
- Completed enrollment in ALPHA-ORBIT, the pivotal study of navenibart, with top-line results expected in Q3 2027.
- Improved full-year 2026 non-GAAP operating expense outlook to $420 million to $440 million.
Price Impact
More from BCRX